A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Paul G. Richardson, Wanling.

Slides:

Advertisements

Similar presentations

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma by Paul G. Richardson,

Advertisements

Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.

Multiple Myeloma Update from the American Society of Clinical Oncology (ASCO) 43 rd Annual Meeting Welcome and Introduction Nikhil Munshi, MD Dana-Farber.

A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,

Durable remissions with autologous stem cell transplantation for high-risk HIV-associated lymphomas by Amrita Krishnan, Arturo Molina, John Zaia, David.

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Volume 12, Issue 3, Pages (March 2011)

Pomalidomide Plus Low-Dose Dex vs High-Dose Dex in Rel/Ref Myeloma

Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination with Low-Dose Dexamethasone in Patients with Relapsed and Refractory Multiple.

Andrzej Jakubowiak Seminars in Hematology

Dimopoulos MA et al. Proc ASH 2012;Abstract LBA-6.

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials.

by Robert A. Kyle, Morie A. Gertz, Philip R. Greipp, Thomas E

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts by Boglarka Gyurkocza,

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of.

How I treat multiple myeloma in younger patients

The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma by Jonathan.

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis.

Absence of biologically important Kaposi sarcoma–associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

The utility of plasma vascular endothelial growth factor levels in the diagnosis and follow-up of patients with POEMS syndrome by Anita D'Souza, Suzanne.

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion.

Transplants for the elderly in myeloma

How I treat elderly patients with myeloma

Nonmyeloablative conditioning for relapsed follicular lymphoma

Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report by Antonio Palumbo, Sara.

Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma.

A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid.

A phase 2 study of single-agent carfilzomib (PX A1) in patients with relapsed and refractory multiple myeloma by David S. Siegel, Thomas Martin,

Rafael Fonseca MD Chair, Department of Medicine Mayo Clinic in AZ What is the optimal therapeutic approach for MM patients with bor-len relapsed/refractory.

Temporal Changes in Plerixafor Administration and Hematopoietic Stem Cell Mobilization Efficacy: Results of a Prospective Clinical Trial in Multiple Myeloma

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans by Güllü Topal Görgün, Gregory Whitehill,

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin.

Incidence, clinical course, and prognosis of secondary monoclonal gammopathy of undetermined significance in patients with multiple myeloma by Rishi K.

Primary testicular lymphoma

by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald

Bone Turnover Biomarkers Are Useful In Monitoring Myeloma Bone Disease and As Early Predictor Biomarkers For Relapse Disease In Multiple Myeloma by Kay.

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd,

by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T

Patient-Reported Outcomes from a Global Phase 3 Randomized Controlled Trial of Inotuzumab Ozogamicin Versus Standard of Care Chemotherapy for Relapsed/Refractory.

Chronic graft-versus-host disease

Biology of Blood and Marrow Transplantation

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia by Philip.

Gordon L. Phillips, Steven H. Bernstein, Jane L. Liesveld, Camille N

Manish Sharma, Mei-Jie Zhang, Xiaobo Zhong, Muneer H

Sarah A. Holstein, Paul G. Richardson, Jacob P. Laubach, Philip L

Kamal Kant Singh Abbi, Junting Zheng, Sean M

Boccadoro M et al. Proc ASCO 2011;Abstract 8020.

A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction: results from the UK NCRI AML17 trial in 1206 patients by Alan K. Burnett,

Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients (pts) with Relapsed Multiple Myeloma (MMY1001): An Open-Label, Phase 1b Study.

Athanasios Anagnostopoulos, Parameswaran N. Hari, Waleska S

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM by Sundar Jagannath, Rafat Abonour,

Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar,

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis by Samuel Yamshon,

Overall Survival (OS) of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus.

Tandem autologous/allogeneic hematopoietic cell transplantation with bortezomib maintenance therapy for high-risk myeloma by Damian J. Green, David G.

Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma by Tomer M. Mark, Peter A. Forsberg, Adriana.

Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia by Benjamin L. Lampson, Haesook T. Kim, Matthew.

Treatment versus Transplant for Challenging Hematologic Disorders

High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis.

Treatment options for relapsed and refractory multiple myeloma

Selinexor and Low Dose Dexamethasone (Sd) in Patients with Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib and Anti-CD38 Ab Refractory Multiple Myeloma.

Mesenchymal Stem Cell-Derived Vesicles Reverse Hematopoietic Radiation Damage by Sicheng Wen, Laura R Goldberg, Mark S Dooner, John L Reagan, and Peter.

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary.

by Andy Hsu, Hang Quach, Tsin Tai, H. Miles Prince, Simon J

High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term.

by Todd A. Fehniger, Sarah Larson, Kathryn Trinkaus, Marilyn J

Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation.

Cold agglutinin disease

Presentation transcript:

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma by Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lunde, John Feather, Michelle E. Maglio, Diane Warren, Dixil Francis, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Constantine S. Mitsiades, Edie Weller, and Kenneth C. Anderson Blood Volume 123(10):1461-1469 March 6, 2014 ©2014 by American Society of Hematology

(A) PFS and (B) OS for all patients treated with lenalidomide-bortezomib-dexamethasone (censoring at time of transplant, n = 5). (A) PFS and (B) OS for all patients treated with lenalidomide-bortezomib-dexamethasone (censoring at time of transplant, n = 5). Estimated 6-, 12-, and 24-month PFS rates were 75% (95% CI, 62-84), 36% (95% CI, 24-48), and 15% (95% CI, 7-25), respectively. Estimated 12- and 24-month OS rates were 89% (95% CI, 77-84) and 65% (95% CI, 51-76), respectively. Paul G. Richardson et al. Blood 2014;123:1461-1469 ©2014 by American Society of Hematology